Nucleotide Metabolism in Health and Disease

Xiaoying Zhao(Handan College), Rui Liu(Sichuan University), Hassna Soummane(Cadi Ayyad University), Jingyi Li(China National Nuclear Corporation), Yike Xu(City University of Hong Kong), Mouna Khouchani(Cadi Ayyad University), Shu Rao(Sichuan University), Yiyu Zeng(Sichuan University)

MedComm

August 1, 2026

10.1002/mco2.70900

Cited by 0

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247

Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

|BMC Cancer|2014|146

Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

|PLoS ONE|2015|115